Monash University to study role of aspirin in prevention of dementia

5 January 2015

The humble aspirin, originally used only as a pain killer but since has been identified as a factor in the fight against heart attacks and strokes, could also have an important role in the prevention of dementia.

Australia’s Monash University has been commissioned by the US National Institutes of Health to investigate aspirin’s anti-dementia powers. The Melbourne-based university has begun a A$50 million ($41 million) trial called ASPirin in Reducing Events in the Elderly (ASPREE). It is a joint study with the Berman Center for Outcomes and Clinical Research in Minneapolis, USA.

According to a Monash University statement, aspirin, which was commercialized by Germany’s Bayer more than 200 years ago, may help older people to live well for longer by delaying the onset of illnesses in the first place. In fact, previous studies have shown that low dose aspirin:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK